Corpus ID: 6133836

Effects of defibrotide on leukocyte-endothelial cell interaction in the rat mesenteric vascular bed: role of P-selectin.

  title={Effects of defibrotide on leukocyte-endothelial cell interaction in the rat mesenteric vascular bed: role of P-selectin.},
  author={R. Scalia and L. Kochilas and B. Campbell and A. Lefer},
  journal={Methods and findings in experimental and clinical pharmacology},
  volume={18 10},
The effects of defibrotide on leukocyte-endothelial cell interaction and P-selectin surface expression on the microvascular endothelium were investigated. Intravital microscopy was performed in the rat mesenteric microcirculation. The rat mesentery was superfused either with Krebs-Henseleit solution (i.e., control) or 50 microM NG nitro-L-arginine methyl ester (L-NAME). Defibrotide (40 mg/kg) was intravenously infused to control rats and to L-NAME superfused rats. P-selectin expression on… Expand
Defibrotide modulates prostaglandin production in the rat mesenteric vascular bed.
  • H. Peredo
  • Biology, Medicine
  • Prostaglandins, leukotrienes, and essential fatty acids
  • 2002
The present results show that defibrotide modulates PG production in the mesenteric bed and that the observed inhibition of the contractile responses should be due to the impairment of the NA-induced increase in PGF(2alpha) release. Expand
Vascular protection by estrogen in ischemia-reperfusion injury requires endothelial nitric oxide synthase.
It is concluded that the protective effect of estrogen, as measured by leukocyte rolling and adhesion, is significantly reduced in eNOS(-/-) mice, suggesting that induction of eN OS activity is the major mechanism of vasoprotection by estrogen in this model. Expand
Chronic oral defibrotide counteracts hypercholesterolemia noxious effects on cardiovascular function in the rabbit.
Oral defibrotide counteracted the parameters associated with early endothelial cell disfunction: that is, increased adherence of leukocytes to endothelium and endothelial vasorelaxation induced by acetylcholine, which acts through the release of endotHelium-derived relaxing factor. Expand
Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice.
It is demonstrated that Defibrotide synergizes with rhG-CSF and significantly increases the mobilization of a broad spectrum of PBPCs, including primitive and committed progenitor cells, which might have relevant implications for autologous and allogeneic anticancer therapy in humans. Expand
Defibrotide Interferes With Several Steps of the Coagulation-Inflammation Cycle and Exhibits Therapeutic Potential to Treat Severe Malaria
Results imply that aptameric sequences and adenosine receptor mediate dendritic cells responses to the drug imply thatTherapeutic use of DF in malaria is proposed. Expand
Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor.
The data demonstrate that in nonhuman primates: 1) defibrotide enhances rhG-CSF-elicited mobilization of primitive and committed progenitors; and 2) a 2-day defib rotide injection is as effective as a 5-day injection. Expand
The use of defibrotide in blood and marrow transplantation.
In a phase 3 prophylaxis trial, defibrotide was found to lower incidence of VOD/SOS in children in children (not an approved indication) and reduce the incidence of graft-versus-host disease. Expand
Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome
Defibrotide appears to protect endothelial cells and restore the thrombolytic–fibrinolytic balance and has demonstrated favorable Day +100 survival and overall adverse-event rates that seem similar to control groups receiving supportive care alone. Expand
Defibrotide: properties and clinical use of an old/new drug.
The present work reviews the more important experimental and clinical studies performed to detect DFT effects and considers DFT on the whole as a drug able to protect endothelium against activation. Expand
Defibrotide: A Review of Its Use in Severe Hepatic Veno-Occlusive Disease Following Haematopoietic Stem Cell Transplantation
Intravenous defibrotide was generally well tolerated in patients with severe hepatic VOD following HSCT, and was not associated with an increased risk of haemorrhagic adverse events. Expand